Dr. Andersen-Nissen is a principal staff scientist in the Vaccine and Infectious Disease Division of Fred Hutch and directs the Cape Town HVTN Immunology Lab in South Africa. She joined the HVTN in 2011 and leads cellular and innate immunology studies of HIV, TB and COVID vaccines to understand vaccine immunogenicity and immune correlates of risk and protection.

Dr. Andrasik is a clinical health psychologist working to build and enhance partnerships with communities in clinical research. She has led a robust Social and Behavioral Sciences research agenda for the HVTN for over a decade.  She has extensive experience working with communities and community organizations. Her areas of expertise include community based participatory research and qualitative methods.

Dr. Andriesen works with Network leadership and study teams to facilitate acquisition of data and conduct of analyses across the breadth of the HVTN research portfolio. Having been with the HVTN for more than a decade, she serves as a point of contact for all things data and has a special interest in the application of new technologies for the conduct of clinical trials.

Sally Bock has over 25 years of experience in brand marketing. She joined the CoVPN after leading the Fred Hutch marketing team. Her experience ranges from Fortune 500 companies to emerging brands, as well as across many high-impact sectors, including health care, technology (SaaS, Cloud, satellite), consumer brands, social impact, higher education, and arts & culture institutions.

Preston is an infectious diseases clinician, educator and vaccine researcher caring for persons living with HIV since the early 1980s. His most recent work has been with early phase clinical trials of pre-erythrocytic malaria vaccines and he brings that experience to the design and conduct of early phase HIV vaccine and monoclonal antibody trials.

Dr. Furch works on HIV vaccine development and trial design, mucosal immunology in HIV prevention trials, and harm reduction at the intersection of HIV and neglected infectious disease; thereby decreasing rates of morbidity caused by preventable illness.

Huub Gelderblom is a physician-scientist who joined HVTN in 2019 and again in 2022. Huub has an MD, MSc and PhD from the University of Amsterdam, and an MPH from New York University. He has extensive experience working on HIV, hepatitis C, trachoma and SARS-CoV-2 in Europe, Africa, and the US. Huub works on the clinical development for broadly neutralizing antibodies for HIV prevention (also known as passive immunization and passive immunoprophylaxis).

William Hahn is clinically trained in infectious disease. During fellowship, his research experience involved the link between the innate and adaptive immune response in preclinical models of malaria. He joined the HVTN in 2019 and has worked primarily on early-phase vaccine trials.

Dr. Hural holds a PhD in Immunology and Molecular Pathogenesis and has over 25 years of experience in vaccine development and clinical trials. He has led the HVTN Laboratory Operations group for more than two decades. This group oversees and coordinates all laboratory activities related to HVTN clinical trials, including immunologic and virologic endpoint monitoring, specimen processing, HIV diagnostics, viral genetics, specimen repositories, and safety testing.

Carissa Karg joined the HVTN in 2009 and is the Senior Director of Network Operations. Prior to her current role, she was a Clinical Trials Manager, the Associate Director of Site Operations, and the Director of Site Operations at the HVTN. She has a wealth of experience with implementation, oversight, and operations of HVTN HIV vaccine and antibody clinical trials. She has an MPH with a special interest in HIV/AIDS and other infectious diseases.

Shelly Ramirez serves as the Director of Site Operations at the HVTN LOC. She embarked on her journey with the HVTN at SCHARP in 2005 as a Project Manager. She joined the HVTN LOC in 2011 as a Clinical Trials Manager. She was the Associate Director of Site Operations before assuming her current role. Shelly holds a Master’s degree, which complements her extensive experience in clinical trial operations and site development and oversight.

Laurie Rinn is a public health professional with more than 20 years of experience in clinical research in the non-profit and global health fields. She has worked in project management, clinic coordination, and regulatory affairs in the fields of oncology, malaria and COVID-19 and HIV vaccine research.

As the Associate Director of Finance and Contracts at Fred Hutch, Vivianne Rotich oversees the full cycle financial activities including clinical trials budgeting, financial reporting and management, and serves as the point of contact on financial matters.

Dr. Roxby is a physician-scientist and Associate Professor of Medicine, Global Health and Epidemiology at University of Washington. Dr. Roxby’s research focuses on HIV and STI prevention in women and strategies to prevent Covid-19. Roxby works to expand the HVTN to include the next generation of HIV vaccine researchers.

As External Relations Director, Louis leads the engagement of external partners and public communications for the HVTN and CoVPN. Louis’ work includes guiding HVTN/CoVPN stakeholder engagement strategies, spearheading community partnerships, crafting external study communications, and developing research awareness and educational initiatives.

Dr. Tapley is a physician-scientist who serves as a liaison between clinical research site staff and leadership based in Southern Africa, and HVTN Core based in Seattle. Dr. Tapley completed his M.D. at UCSF, M.Sc. at UC Berkeley, and Internal Medicine residency at Johns Hopkins Bayview before pursuing infectious disease training at the University of Washington. He focuses on TB, HIV, and Covid-19 research.

Dr. Villaran is a graduate of the Universidad Peruana Cayetano Heredia Medical School in Lima, Peru, received a Master of Science in International Public Health and Tropical Disease from Humboldt University Berlin, Germany and a Master of Public Health from the University of Washington.